Перейти к содержимому
Bending the Curve Trial by Trial
?EN

Назад: Рак поджелудочной железы

Список литературы: Рак поджелудочной железы

77 источников, процитированных на этой странице. Ссылки ведут к первоисточнику.

  1. Whipple AO, Parsons WB, Mullins CR. TREATMENT OF CARCINOMA OF THE AMPULLA OF VATER. Ann Surg. 1935;102(4):763-79. PubMedDOI
    ЦитироватьЗагрузка…
  2. Herlyn M, Sears HF, Steplewski Z, Koprowski H. Monoclonal antibody detection of a circulating tumor-associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma. J Clin Immunol. 1982;2(2):135-40. PubMedDOI
    ЦитироватьЗагрузка…
  3. Del Villano BC, Brennan S, Brock P, Bucher C, Liu V, McClure M, et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem. 1983;29(3):549-52. PubMed
    ЦитироватьЗагрузка…
  4. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988;53(4):549-54. PubMedDOI
    ЦитироватьЗагрузка…
  5. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol. 1990;85(4):350-5. PubMed
    ЦитироватьЗагрузка…
  6. US Food and Drug Administration. Approval package, Gemzar (gemcitabine hydrochloride) for Injection, NDA 20-509, Eli Lilly and Company; approval letter dated 15 May 1996 (scanned image document in the Drugs@FDA archive). Источник
  7. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403-13. PubMedDOI
    ЦитироватьЗагрузка…
  8. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358(9293):1576-85. PubMedDOI
    ЦитироватьЗагрузка…
  9. ClinicalTrials.gov. NCT00088894 (CALGB-80303 listed as a secondary id). Registry record accessed 21 October 2026. NCT00088894
  10. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200-10. PubMedDOI
    ЦитироватьЗагрузка…
  11. US Food and Drug Administration. Supplement approval letter, Tarceva (erlotinib) tablets, NDA 21-743/S-003, OSI Pharmaceuticals, Inc.; electronically signed 2 November 2005 (five-page document). Источник
  12. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267-77. PubMedDOI
    ЦитироватьЗагрузка…
  13. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321(5897):1801-6. PubMedDOI
    ЦитироватьЗагрузка…
  14. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28(22):3617-22. PubMedDOI
    ЦитироватьЗагрузка…
  15. Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010;28(22):3605-10. PubMedDOI
    ЦитироватьЗагрузка…
  16. Are C, Dhir M, Ravipati L. History of pancreaticoduodenectomy: early misconceptions, initial milestones and the pioneers. HPB (Oxford). 2011;13(6):377-84. PubMedDOI
    ЦитироватьЗагрузка…
  17. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-25. PubMedDOI
    ЦитироватьЗагрузка…
  18. Canto MI, Hruban RH, Fishman EK, Kamel IR, Schulick R, Zhang Z, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology. 2012;142(4):796-804; quiz e14-5. PubMedDOI
    ЦитироватьЗагрузка…
  19. US Food and Drug Administration. Approval package, Abraxane (paclitaxel protein-bound particles), NDA 21660/S-037, Abraxis BioScience, LLC; supplement approval letter signed 6 September 2013. Источник
  20. Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473-81. PubMedDOI
    ЦитироватьЗагрузка…
  21. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691-703. PubMedDOI
    ЦитироватьЗагрузка…
  22. US Food and Drug Administration. NDA approval letter, Onivyde (irinotecan liposome injection), NDA 207793, Merrimack Pharmaceuticals, Inc.; electronically signed 22 October 2015. Источник
  23. Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst. 2015;107(2). PubMedDOI
    ЦитироватьЗагрузка…
  24. Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47-52. PubMedDOI
    ЦитироватьЗагрузка…
  25. ClinicalTrials.gov. NCT02715804 (HALO 109-301). Registry record accessed 21 October 2026. NCT02715804
  26. US Food and Drug Administration. Prescribing information, Keytruda (pembrolizumab), revised 05/2017 (BLA 125514/S-014 labeling). Источник
  27. US Food and Drug Administration. Approval letter, BLA 125514/S-14, Keytruda (pembrolizumab), Merck Sharp and Dohme Corp.; electronically signed 23 May 2017. Источник
  28. Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011-1024. PubMedDOI
    ЦитироватьЗагрузка…
  29. Canto MI, Almario JA, Schulick RD, Yeo CJ, Klein A, Blackford A, et al. Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Gastroenterology. 2018;155(3):740-751.e2. PubMedDOI
    ЦитироватьЗагрузка…
  30. Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018;379(25):2395-2406. PubMedDOI
    ЦитироватьЗагрузка…
  31. US Food and Drug Administration. Accelerated approval letter, Vitrakvi (larotrectinib) capsules, NDA 210861, Loxo Oncology, Inc.; signed 26 November 2018. Источник
  32. Isaji S, Mizuno S, Windsor JA, Bassi C, Fernández-Del Castillo C, Hackert T, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18(1):2-11. PubMedDOI
    ЦитироватьЗагрузка…
  33. Sohal DPS, Kennedy EB, Khorana A, Copur MS, Crane CH, Garrido-Laguna I, et al. Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018;36(24):2545-2556. PubMedDOI
    ЦитироватьЗагрузка…
  34. US Food and Drug Administration. Supplement approval letter (replacement), Lynparza (olaparib) tablets, NDA 208558/S-010, AstraZeneca Pharmaceuticals L.P.; signed 27 December 2019. Источник
  35. Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019;381(4):317-327. PubMedDOI
    ЦитироватьЗагрузка…
  36. US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al. Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA. 2019;322(5):438-444. PubMedDOI
    ЦитироватьЗагрузка…
  37. Goggins M, Overbeek KA, Brand R, Syngal S, Del Chiaro M, Bartsch DK, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut. 2020;69(1):7-17. PubMedDOI
    ЦитироватьЗагрузка…
  38. Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38(1):1-10. PubMedDOI
    ЦитироватьЗагрузка…
  39. Sohal DPS, Kennedy EB, Cinar P, Conroy T, Copur MS, Crane CH, et al. Metastatic Pancreatic Cancer: ASCO Guideline Update. J Clin Oncol. 2020;38(27):3217-3230. PubMedDOI
    ЦитироватьЗагрузка…
  40. Van Cutsem E, Tempero MA, Sigal D, Oh DY, Fazio N, Macarulla T, et al. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. J Clin Oncol. 2020;38(27):3185-3194. PubMedDOI
    ЦитироватьЗагрузка…
  41. Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, et al. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol. 2020;38(16):1763-1773. PubMedDOI
    ЦитироватьЗагрузка…
  42. Conroy T, Castan F, Lopez A, Turpin A, Ben Abdelghani M, Wei AC, et al. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. JAMA Oncol. 2022;8(11):1571-1578. PubMedDOI
    ЦитироватьЗагрузка…
  43. Kindler HL, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. J Clin Oncol. 2022;40(34):3929-3939. PubMedDOI
    ЦитироватьЗагрузка…
  44. Overbeek KA, Levink IJM, Koopmann BDM, Harinck F, Konings ICAW, Ausems MGEM, et al. Long-term yield of pancreatic cancer surveillance in high-risk individuals. Gut. 2022;71(6):1152-1160. PubMedDOI
    ЦитироватьЗагрузка…
  45. Versteijne E, van Dam JL, Suker M, Janssen QP, Groothuis K, Akkermans-Vogelaar JM, et al. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. J Clin Oncol. 2022;40(11):1220-1230. PubMedDOI
    ЦитироватьЗагрузка…
  46. Bekaii-Saab TS, Yaeger R, Spira AI, Pelster MS, Sabari JK, Hafez N, et al. Adagrasib in Advanced Solid Tumors Harboring a KRAS(G12C) Mutation. J Clin Oncol. 2023;41(25):4097-4106. PubMedDOI
    ЦитироватьЗагрузка…
  47. Conroy T, Pfeiffer P, Vilgrain V, Lamarca A, Seufferlein T, O'Reilly EM, et al. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(11):987-1002. PubMedDOI
    ЦитироватьЗагрузка…
  48. US Food and Drug Administration. Supplement approval letter, BLA 125514/S-132, Keytruda (pembrolizumab), Merck Sharp & Dohme Corp.; electronically signed 28 March 2023 (fulfilment of postmarketing requirements PMR 3213-1 and 3213-2). Источник
  49. Strickler JH, Satake H, George TJ, Yaeger R, Hollebecque A, Garrido-Laguna I, et al. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. N Engl J Med. 2023;388(1):33-43. PubMedDOI
    ЦитироватьЗагрузка…
  50. Tempero MA, Pelzer U, O'Reilly EM, Winter J, Oh DY, Li CP, et al. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2023;41(11):2007-2019. PubMedDOI
    ЦитироватьЗагрузка…
  51. Wainberg ZA, Melisi D, Macarulla T, Pazo Cid R, Chandana SR, De La Fouchardière C, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402(10409):1272-1281. PubMedDOI
    ЦитироватьЗагрузка…
  52. US Food and Drug Administration. BLA accelerated approval letter, Bizengri (zenocutuzumab-zbco) injection, BLA 761352, Merus N.V.; electronically signed 4 December 2024. Источник
  53. US Food and Drug Administration. Supplement approval letter, Onivyde (irinotecan liposome injection), NDA 207793/S-016, Ipsen Biopharmaceuticals, Inc.; electronically signed 13 February 2024. Источник
  54. Labori KJ, Bratlie SO, Andersson B, Angelsen JH, Biörserud C, Björnsson B, et al. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2024;9(3):205-217. PubMedDOI
    ЦитироватьЗагрузка…
  55. Babiker HM, Picozzi V, Chandana SR, Melichar B, Kasi A, Gang J, et al. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study. J Clin Oncol. 2025;43(21):2350-2360. PubMedDOI
    ЦитироватьЗагрузка…
  56. US Food and Drug Administration. Supplement approval letter (fulfillment of postmarketing requirement), Vitrakvi (larotrectinib), NDA 210861/S-012, Bayer HealthCare Pharmaceuticals, Inc.; electronically signed 9 April 2025. Источник
  57. Janssen QP, van Dam JL, van Bekkum ML, Bonsing BA, Bos H, Bosscha KP, et al. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial. Lancet Oncol. 2025;26(10):1346-1356. PubMedDOI
    ЦитироватьЗагрузка…
  58. US Food and Drug Administration (openFDA drug label API). Lumakras (sotorasib) prescribing information, Indications and Usage section, label effective 22 January 2025 (version 19); read 21 October 2026. Источник
  59. Schram AM, Goto K, Kim DW, Macarulla T, Hollebecque A, O'Reilly EM, et al. Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer. N Engl J Med. 2025;392(6):566-576. PubMedDOI
    ЦитироватьЗагрузка…
  60. Conroy T, Ducreux M. ESMO Clinical Practice Guideline Express Update on daraxonrasib in the treatment of metastatic pancreatic cancer. Ann Oncol. 2026;. PubMedDOI
    ЦитироватьЗагрузка…
  61. ClinicalTrials.gov. NCT04340141 (A021806). Registry record, API v2, accessed 21 October 2026. NCT04340141
  62. ClinicalTrials.gov. NCT04927780 (PREOPANC-3). Registry record, API v2, accessed 21 October 2026. NCT04927780
  63. ClinicalTrials.gov. NCT06608927 (PRISM-1). Registry record, API v2, accessed 21 October 2026. NCT06608927
  64. ClinicalTrials.gov. NCT07252232 (RASolute 304). Registry record, API v2, accessed 21 October 2026. NCT07252232
  65. ClinicalTrials.gov. NCT07491445 (RASolute 303). Registry record, API v2, accessed 21 October 2026. NCT07491445
  66. ClinicalTrials.gov. NCT07621718 (RASolute 305). Registry record, API v2, accessed 21 October 2026. NCT07621718
  67. European Medicines Agency. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2026. Page dated 16 October 2026. Источник
  68. US Food and Drug Administration. Premarket Approval (PMA) database record P250034, Optune Pax (Novocure GmbH); decision date 11 February 2026 (approval order letter dated February 11, 2026, and Summary of Safety and Effectiveness Data also read); database page last updated 19 October 2026; read 21 October 2026. Источник
  69. US Food and Drug Administration. FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma (Resources for Information | Approved Drugs). Page content current as of 26 August 2026; read 21 October 2026. Источник
  70. US Food and Drug Administration. NDA approval letter, Rasonque (daraxonrasib) tablets, NDA 220910, Revolution Medicines, Incorporated; electronically signed 26 August 2026. Источник
  71. Ko AH, Malafa MP, Aguilera T, Basturk O, Benson AB 3rd, Cardin DB, et al. Pancreatic Adenocarcinoma, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2026;24(10). PubMedDOI
    ЦитироватьЗагрузка…
  72. US Food and Drug Administration (openFDA drug label API). Bizengri (zenocutuzumab-zbco) prescribing information, Indications and Usage section, label effective 19 May 2026 (version 3); read 21 October 2026. Источник
  73. US Food and Drug Administration (openFDA drug label API). Krazati (adagrasib) prescribing information, Indications and Usage section, label effective 25 March 2026 (version 13); read 21 October 2026. Источник
  74. O'Reilly EM, Wainberg ZA, Hendifar AE, Borad MJ, Pietrantonio F, Pant S, et al. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. N Engl J Med. 2026;395(4):325-337. PubMedDOI
    ЦитироватьЗагрузка…
  75. Schram AM, Yang SR, Kahn G, Velasco R, Repetto M, Kinh Gian Do R, et al. NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer. J Natl Cancer Inst. 2026;118(5):847-855. PubMedDOI
    ЦитироватьЗагрузка…
  76. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER Cancer Stat Facts: Pancreatic Cancer. Page accessed 21 October 2026; the page displays no update date (its HTTP Last-Modified header and last_modified meta tag read 22 April 2026). Источник
  77. Wolpin BM, Park W, Garrido-Laguna I, Spira A, Starodub A, Sommerhalder D, et al. Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer. N Engl J Med. 2026;394(18):1790-1802. PubMedDOI
    ЦитироватьЗагрузка…